Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.
Breaking a longstanding impasse in our understanding of olfaction, scientists at UC San Francisco (UCSF) have created the first molecular-level, 3D picture of how an odor molecule activates a human odorant receptor, a crucial step in deciphering the sense of smell.
Investigators at USC’s Keck School of Medicine directed the meta-analysis, which discovered nine new genetic variants that boost the risk of prostate cancer in an under researched population, including a genetic risk score connected to aggressive forms of the disease.
A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.
The protein SPOP, which also plays a role in endometrial, uterine, and other cancers, is the most mutated in prostate cancer. Despite its significance, it is still unclear how SPOP mutations cause cancer.
Certain prostate cancer patients have genetic mutations that could affect how they are treated. According to a study published in Urology Practice®, an Official Journal of the American Urological Association (AUA), a comprehensive, on-site genetic testing program developed by urologists could help close the gap for this underutilized resource.
Proteins constantly interact with one another inside cells to perform various tasks. Blocking the binding of two or more proteins appears as a potential treatment for some diseases where these functions are altered.
Mutations in the BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 persons, respectively, elevate the risk of various malignancies such as ovarian, breast, pancreatic, and prostate cancer considerably.
Acknowledging which cells lend credence to which regions of cancer can help us better understand how a tumor has expanded and developed over time, such as how it has altered genetically.
Prostate cancer that has spread to other regions of the body is commonly treated with hormone treatment, but many individuals develop resistance to it, making their disease more aggressive and potentially fatal.
CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.
Researchers are rushing to review a group of bacteria known as actinomycetes, which are one of the most successful sources of treatment.
Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer.
Cedars-Sinai scientists discovered that attacking a protein present in prostate cancer cells could stop the disease from further spreading to various other parts of the body.
The detection and quantification of cancer-associated molecular biomarkers in body fluids, or liquid biopsies, prove minimally invasive in early cancer diagnostics.
A new analysis has uncovered a potential link between higher prostate cancer risk and genetic variants associated with higher bloodstream levels of the cholesterol-transporting molecule lipoprotein A.
Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly.
Prostate cancer is the most commonly diagnosed cancer in men and is among the top five causes of cancer-related death. In most cases, prostate cancer can be successfully treated but there is a group of patients who suffer an aggressive course and often fatal outcome.
Cleveland Clinic researchers have shown for the first time that diet-associated molecules in the gut are associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. Findings from the study were published in Cancer Epidemiology, Biomarkers & Prevention.
A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy.